Patient and clinical characteristics
Characteristic . | All patients . | DLI . |
---|---|---|
Total no. of patients studied | 446 | 53 |
Median age, y (range) | 54 (5-74) | 56 (24-72) |
Sex, no. M/F | 285/161 | 42/11 |
Sibling donor/unrelated donor, no. patients | 306/140 | 52/1 |
Graft source, PBSC/BM, no. patients | 426/20 | 53/0 |
Conditioning, no. patients | ||
TBI only | 112 | 32 |
Fludarabine/TBI | 334 | 21 |
Disease, no. patients | ||
MM | 106 | 9 |
NHL | 76 | 4 |
Follicular | 10 | 0 |
High grade | 28 | 2 |
Mantle cell | 21 | 0 |
Other | 17 | 2 |
MDS | 69 | 10 |
AML | 55 | 9 |
CLL | 37 | 6 |
CML | 37 | 5 |
HD | 24 | 5 |
ALL | 12 | 1 |
Myeloproliferative disorders | 9 | 0 |
Renal carcinoma | 13 | 2 |
Cervical carcinoma | 2 | 0 |
Breast carcinoma | 2 | 1 |
Osteosarcoma | 1 | 0 |
Melanoma | 3 | 1 |
Median time to DLI from transplantation, d (range) | — | 99 (48-1228) |
Median follow-up from DLI for patients alive, mo (range) | — | 30 (4-59) |
Characteristic . | All patients . | DLI . |
---|---|---|
Total no. of patients studied | 446 | 53 |
Median age, y (range) | 54 (5-74) | 56 (24-72) |
Sex, no. M/F | 285/161 | 42/11 |
Sibling donor/unrelated donor, no. patients | 306/140 | 52/1 |
Graft source, PBSC/BM, no. patients | 426/20 | 53/0 |
Conditioning, no. patients | ||
TBI only | 112 | 32 |
Fludarabine/TBI | 334 | 21 |
Disease, no. patients | ||
MM | 106 | 9 |
NHL | 76 | 4 |
Follicular | 10 | 0 |
High grade | 28 | 2 |
Mantle cell | 21 | 0 |
Other | 17 | 2 |
MDS | 69 | 10 |
AML | 55 | 9 |
CLL | 37 | 6 |
CML | 37 | 5 |
HD | 24 | 5 |
ALL | 12 | 1 |
Myeloproliferative disorders | 9 | 0 |
Renal carcinoma | 13 | 2 |
Cervical carcinoma | 2 | 0 |
Breast carcinoma | 2 | 1 |
Osteosarcoma | 1 | 0 |
Melanoma | 3 | 1 |
Median time to DLI from transplantation, d (range) | — | 99 (48-1228) |
Median follow-up from DLI for patients alive, mo (range) | — | 30 (4-59) |
PBSC indicates peripheral blood stem cells; BM, bone marrow; and —, not applicable.